C A Marra1, D M Patrick, F Marra. 1. Department of Pharmacy, Vancouver Hospital and Health Sciences Centre, BC.
Abstract
BACKGROUND: Delivery of the pneumococcal vaccine (PCV) to street-involved, HIV patients in British Columbia is low due to poor compliance. Since the use of PCV is expected to reduce morbidity and mortality, it may be more cost-effective to provide the vaccine directly to clinics. METHODS: Three strategies were compared for a cohort of 5000 patients: 1) administering PCV at the clinics; 2) giving a prescription for PCV and expecting patients to fill it at a pharmacy and return for administration; and 3) no administration of vaccine. Decision analysis was utilized to map the costs and outcomes of the patients over 5 years and conduct an incremental cost-effectiveness analysis from the perspective of the Ministry of Health. RESULTS: The average cost per patient was the lowest in Strategy 1 ($549) compared to Strategy 2 ($702) and Strategy 3 ($714). For the cohort, Strategy 1 prevented 269 and 299 additional cases of pneumococcal disease and resulted in a cost savings of $535,000 and $595,000 in direct medical costs when compared to Strategies 2 and 3, respectively. The model was robust to extensive sensitivity analyses. CONCLUSIONS: The Ministry of Health should supply PCV to clinics involved in the care of street-involved HIV patients as this is the most cost-effective strategy.
BACKGROUND: Delivery of the pneumococcal vaccine (PCV) to street-involved, HIVpatients in British Columbia is low due to poor compliance. Since the use of PCV is expected to reduce morbidity and mortality, it may be more cost-effective to provide the vaccine directly to clinics. METHODS: Three strategies were compared for a cohort of 5000 patients: 1) administering PCV at the clinics; 2) giving a prescription for PCV and expecting patients to fill it at a pharmacy and return for administration; and 3) no administration of vaccine. Decision analysis was utilized to map the costs and outcomes of the patients over 5 years and conduct an incremental cost-effectiveness analysis from the perspective of the Ministry of Health. RESULTS: The average cost per patient was the lowest in Strategy 1 ($549) compared to Strategy 2 ($702) and Strategy 3 ($714). For the cohort, Strategy 1 prevented 269 and 299 additional cases of pneumococcal disease and resulted in a cost savings of $535,000 and $595,000 in direct medical costs when compared to Strategies 2 and 3, respectively. The model was robust to extensive sensitivity analyses. CONCLUSIONS: The Ministry of Health should supply PCV to clinics involved in the care of street-involved HIVpatients as this is the most cost-effective strategy.
Authors: J B Robbins; R Austrian; C J Lee; S C Rastogi; G Schiffman; J Henrichsen; P H Mäkelä; C V Broome; R R Facklam; R H Tiesjema Journal: J Infect Dis Date: 1983-12 Impact factor: 5.226
Authors: E D Shapiro; A T Berg; R Austrian; D Schroeder; V Parcells; A Margolis; R K Adair; J D Clemens Journal: N Engl J Med Date: 1991-11-21 Impact factor: 91.245
Authors: R E Hirschtick; J Glassroth; M C Jordan; T C Wilcosky; J M Wallace; P A Kvale; N Markowitz; M J Rosen; B T Mangura; P C Hopewell Journal: N Engl J Med Date: 1995-09-28 Impact factor: 91.245
Authors: Andrew J Leidner; Neil Murthy; Harrell W Chesson; Matthew Biggerstaff; Charles Stoecker; Aaron M Harris; Anna Acosta; Kathleen Dooling; Carolyn B Bridges Journal: Vaccine Date: 2018-12-04 Impact factor: 3.641